Phase 3 Checkmate-025, Evaluating Nivolumab in RCC, Stopped Early

Nivolumab proved superior to everolimus in improving overall survival in previously treated patients.

In a press release from earlier today, Bristol Myer's Squibb, the developer of nivolumab, announced that the phase 3 Checkmate-025 trial was halted early by an independent Data Monitoring Committee following significantly better overall survival of patients receiving nivolumab, compared with the control. The trial was evaluating the efficacy of nivolumab versus everolimus in previously treated renal cell carcinoma patients.

“Through our Opdivo clinical development program, we aim to redefine treatment expectations for patients with advanced RCC by providing improved survival,” said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb.

Read the complete press release here: http://bit.ly/1LxXiK6